Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.66 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.56 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | GLA | P06280 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.51 |
| ▸ | NQO2 | P16083 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.49 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21585560 | 0.86 | TDP1 (0.66) | TDP1ALDH1A1GLAHPGDLMNA | |
| SCHEMBL8573022 | 0.81 | TDP1 (0.64) | TDP1MTNR1AMTNR1BALDH1A1MEN1 | |
| SCHEMBL31332133 | 0.81 | TDP1 (0.64) | TDP1MTNR1AMTNR1BCYP2C9MEN1 | |
| SCHEMBL3581821 | 0.81 | TDP1 (0.64) | TDP1MTNR1AMTNR1BCYP2C9MEN1 | |
| SCHEMBL3587711 | 0.81 | TDP1 (0.64) | TDP1MTNR1AMTNR1BALDH1A1GLA | |
| SCHEMBL24821196 | 0.81 | TDP1 (0.64) | TDP1MTNR1AMTNR1BCYP2C9TSHR | |
| SCHEMBL9572176 | 0.81 | TDP1 (0.64) | TDP1MTNR1AMTNR1BALDH1A1GLA | |
| SCHEMBL7237625 | 0.81 | MTNR1A (0.58) | TDP1MTNR1AMTNR1BALDH1A1GLA | |
| SCHEMBL6076163 | 0.81 | MTNR1A (0.58) | MTNR1AMTNR1BHPGDLMNANQO2 | |
| SCHEMBL3960876 | 0.80 | MTNR1A (0.60) | MTNR1AMTNR1BNQO2TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | TOHOKU UNIVERSITY (JP) | 2021-10-19 | — | — | US | disclosed |
| US-10463647-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2019-11-05 | — | — | US | disclosed |
| US-10450260-B2 | NO- and H2S-releasing compounds | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2019-10-22 | — | — | US | disclosed |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | TOHOKU UNIVERSITY (JP) | 2019-07-25 | — | — | US | disclosed |
| US-20180353475-A1 | Erythropoietin Expression Promoter | KAKE EDUCATIONAL INSTITUTION (JP) | 2018-12-13 | — | — | US | disclosed |
| EP-2923700-B1 | ERYTHROPOIETIN EXPRESSION PROMOTER | UNIV TOHOKU (JP) | 2018-11-07 | — | — | EP | disclosed |
| US-10004718-B2 | Erythropoietin expression promoter | TOHOKU UNIVERSITY (JP) | 2018-06-26 | — | — | US | disclosed |
| CN-104936591-B | Hematopoietin expression facilitator | 国立大学法人东北大学 | 2018-05-29 | — | — | CN | disclosed |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2017-09-14 | — | — | US | disclosed |
| US-9688607-B2 | No- and H2S-releasing compounds | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2017-06-27 | — | — | US | disclosed |
| CN-104936591-A | Erythropoietin expression promoter | UNIV TOHOKU NAT UNIV CORP | 2015-09-23 | — | — | CN | disclosed |
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (US) | 2014-08-07 | — | — | US | disclosed |
| CN-103874488-A | NO- and H2S- releasing compounds | UNIV CITY NEW YORK RES FOUND | 2014-06-18 | — | — | CN | disclosed |
| CN-1181050-C | Novel substituted dimeric compounds, its preparing process and medicinal compsns. containing same | ɪά��ʵ���� | 2004-12-22 | — | — | CN | disclosed |
| US-6635650-B2 | Such as N-(2-(7-(2-((8-(2-(acetyl-amino)ethyl)-2-naphthyl) oxy)ethoxy)-1-napthyl)ethyl)acetamide for treating or preventing melatoninergic disorders | LES LABORATOIRES SERVIER (FR) | 2003-10-21 | — | — | US | disclosed |
| EP-1038863-B1 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | SERVIER LAB (FR) | 2003-06-04 | — | — | EP | disclosed |
| US-20020035114-A1 | Substituted dimeric compounds | LESIEUR DANIEL (FR) | 2002-03-21 | — | — | US | disclosed |
| US-6319930-B1 | CONTAINING FUSED AROMATIC CARBO- OR HETEROCYCLIC RINGS AND AMIDE, THIOAMIDE, UREA OR THIOUREA GROUPS; USEFUL IN TREATING OR IN PREVENTING MELATONINERGIC DISORDERS. | ADIR ET COMPAGNIE (FR) | 2001-11-20 | — | — | US | disclosed |
| CN-1273967-A | Novel substituted dimeric compounds, its preparing process and medicinal compsns. containing same | ADIR (FR) | 2000-11-22 | — | — | CN | disclosed |
| EP-1038863-A2 | Substituted dimeric compounds, process for their preparation and pharmaceutical compositions thereof | ADIR ET COMPAGNIE (FR) | 2000-09-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221316-A1 | NO- AND H2S- RELEASING COMPOUNDS | PTGS1, NOS2, NOS1 | TDP1 2865/4885MTNR1A 420/4885MTNR1B 621/4885 |
| US-20180353475-A1 | Erythropoietin Expression Promoter | EPOR, NFE2L2, FOXO1 | TDP1 4808/4885MTNR1A 321/4885MTNR1B 326/4885 |
| US-20170260124-A1 | NO- AND H2S- RELEASING COMPOUNDS | NOS2, NOS3, NOS1 | TDP1 2157/4885MTNR1A 171/4885MTNR1B 255/4885 |
| US-10450260-B2 | NO- and H2S-releasing compounds | NOS2, NOS3, NOS1 | TDP1 2157/4885MTNR1A 171/4885MTNR1B 255/4885 |
| US-11147796-B2 | Agent for preventing or ameliorating hearing impairment | SLC26A4, OTC, SLC25A20 | TDP1 2836/4885MTNR1A 191/4885MTNR1B 395/4885 |
| US-20020035114-A1 | Substituted dimeric compounds | NR0B2, NR0B1, NR2C2 | TDP1 3650/4885MTNR1A 4/4885MTNR1B 5/4885 |
| US-20190224165-A1 | Agent for Preventing or Ameliorating Hearing Impairment | SLC26A4, OTC, SLC25A20 | TDP1 2836/4885MTNR1A 191/4885MTNR1B 395/4885 |
| US-10004718-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | TDP1 4808/4885MTNR1A 321/4885MTNR1B 326/4885 |
| US-10463647-B2 | Erythropoietin expression promoter | EPOR, NFE2L2, FOXO1 | TDP1 4808/4885MTNR1A 321/4885MTNR1B 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.